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Abstract
Background: Pro-inflammatory, cytotoxic CD4
+CD28
2 T-cells with known defects in apoptosis have been investigated as
markers of premature immuno-senescence in various immune-mediated diseases. In this study we evaluated the influence
of polyclonal antilymphocyte globulins (ATG-Fresenius, ATG-F) on CD4
+CD28
2 T-cells in vivo and in vitro.
Principal Findings: Surface and intracellular three colour fluorescence activated cell sorting analyses of peripheral blood
mononuclear cells from 16 consecutive transplant recipients and short-term cell lines were performed. In vivo, peripheral
levels of CD3
+CD4
+CD28
2 T-cells decreased from 3.767.1% before to 060% six hours after ATG-F application (P=0.043) in 5
ATG-F treated but not in 11 control patients (2.962.9% vs. 3.963.0%). In vitro, ATG-F induced apoptosis even in CD4
+CD28
2
T-cells, which was 4.3-times higher than in CD4
+CD28
+ T-cells. ATG-F evoked apoptosis was partially reversed by the broad-
spectrum caspase inhibitor benzyloxycarbonyl (Cbz)-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk) and prednisolon-21-
hydrogensuccinate. ATG-F triggered CD25 expression and production of pro-inflammatory cytokines, and induced down-
regulation of the type 1 chemokine receptors CXCR-3, CCR-5, CX3CR-1 and the central memory adhesion molecule CD62L
predominately in CD4
+CD28
2 T-cells.
Conclusion: In summary, in vivo depletion of peripheral CD3
+CD4
+CD28
2 T-cells by ATG-F in transplant recipients was
paralleled in vitro by ATG-F induced apoptosis. CD25 expression and chemokine receptor down-regulation in CD4
+CD28
2 T-
cells only partly explain the underlying mechanism.
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Introduction
Polyclonal antilymphocyte or antithymocyte globulins (ATG)
are potent immunosuppressive agents used in organ transplanta-
tion since the late 1960s. Clinical indications for ATGs include not
only prevention (induction therapy) or rescue treatment of acute
rejection, conditioning for haematopoietic stem cell transplanta-
tion from unrelated HLA-matched or haploidentical donors,
treatment of graft-versus-host-disease [1] and severe aplastic
anaemia [2], but also a rescue therapy in severe and therapy
refractory rheumatic diseases [3,4].
The precise action mechanism of ATGs is still undefined.
Human thymocytes are the most common source of antigens for
the preparation of ATGs, thus including a mixture of multiple
antibodies to various lymphocyte surface antigens [5–7]. Induction
of profound lymphocytopenia as well as functional immunomod-
ulation with down-regulation of leukocyte adhesion molecules,
binding of chemokine receptors and interaction with receptors of
lymphocyte activation [1] have been described as potential
contributors to the immunosuppressive effects of ATGs. Lympho-
cyte depletion is caused by complement-mediated cytolysis,
clearance of lymphocytes through opsonization and phagocytosis
by macrophages, induction of Fas-mediated apoptosis and
Cathepsin B dependent mechanisms of activated and non-
activated lymphocytes [8–10]. Functional antibodies of rabbit
ATGs to leukocyte adhesion molecules and chemokine receptors
impair responses to chemotactic signals and lymphocyte trafficking
to sites of inflammation [7,11]. Furthermore, ATGs trigger
apoptosis in B-cell lineages, interfere with functional properties
of dendritic cells and induce the expansion and activation of
regulatory and natural killer T-cells [12–14].
Recently, a subgroup of pro-inflammatory T-cells has been
identified in patients with various chronic inflammatory diseases
[15–21] and allograft recipients [22,23]. CD4
+CD28
2 T-cells are
resistant against apoptotic stimuli and are suggested to perpetuate
chronic inflammation [24,25]. Clinically, these cells were associ-
ated with the severity of rheumatoid arthritis and rheumatoid
arthritis-associated vasculitis [26–28], ankylosing spondylitis [18],
Wegeners’ granulomatosis [20,21], contributed to plaque instabil-
ity in patients with coronary artery disease [29,30], and were
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following ischemic stroke [31]. Besides, increased levels of
CD4
+CD28
2 T-cells were associated with deterioration of graft
function after kidney and lung transplantation [22,32]. Function-
ally, these T-cells are capable of releasing large amounts of
interferon-c (IFN-c), perforin and granzyme B, providing them
with the possibility to lyse target cells [30]. Especially the cytolytic
proteins perforin and granzyme B are involved in the process of
allograft deterioration and may be useful in predicting graft loss
[33,34]. Overall, CD4
+CD28
2 T-cells are a marker for chronic
inflammation, early aging [35], and compromised immunocom-
petence [36].
Depletion of this ‘‘nasty’’ pro-inflammatory cytotoxic T-cell
subset seems to be a promising new therapeutic approach;
however, up to now, only 33–36% decrement of peripheral
CD4
+CD28
2 T-cells was observed after treatment with the anti-
tumor necrosis factor-a (TNF-a) antibody, infliximab [37–40].
Besides, results from a retrospective, observational study suggest
an even lower reduction of the frequency of peripheral
CD4
+CD28
2 T-cells by statins in unstable angina [41].
The aim of this study was to evaluate the effects of ATG-
Fresenius (ATG-F) on circulating pro-inflammatory
CD3
+CD4
+CD28
2 T-cells. Observing a complete depletion of
this lymphocyte population by ATG-F treatment in vivo, we then
investigated dose-dependent pro-apoptotic and immunomodula-
tory effects of ATG-F on CD4
+CD28
2 T-cells in vitro.
Results
Rapid depletion of circulating CD3
+CD4
+CD28
2 T-cells in
transplant patients treated with polyclonal
antilymphocyte globulins
Demographic data of patients undergoing organ transplantation
with or without ATG-F treatment are shown in Table 1.
In this small pilot study the prevalence of peripheral circulating
CD3
+CD4
+CD28
2 T-cells was tested before and 6 hours after
organ transplantation with and without application of ATG-F.
Results of a blinded laboratory investigator showed that ATG-F
treatment resulted in a total decrement of peripheral T-cells.
Peripheral levels of circulating CD3
+CD4
+CD28
2 T-cells de-
creased from 3.767.1% to 060% (P=0.043) in ATG-F treated
patients, but did not decrease in control patients (2.962.9% and
3.963.0% before and after organ transplantation, respectively,
Figure 1).
Antilymphocyte globulins preferentially trigger apoptosis
in CD4
+CD28
2 T-cells in vitro
In vitro, treatment of short term cell lines with ATG-F resulted in
a preferential reduction of CD3
+CD4
+CD28
2 compared to
CD28
+ T-cells. Figure 2A shows the prevalences of
CD3
+CD4
+CD28
2 after exposure to rabbit IgG and different
doses of ATG-F over 18 hours in a representative example.
Table 1. Patients’ characteristics at enrolment of the study.
ATG treatment* Sex { Age [years] CRP [mg/dl]§ Leukocytes [G/l]¤ Hb [g/l]
concommitant immune-
suppressive therapy{ TX-organ treated condition
N M 56 0.7 9.2 158 CsA, MMF, GC, aIL2R L chronic emphysema
N M 57 2.3 5.0 108 CsA, GC, MMF K chronic GN
N M 46 0.7 4.6 126 aIL2R, FK-506, GC L CirrhHep
N M 43 0.7 8.3 117 aIL2R, FK-506, GC K chronic GN
N M 61 0.7 2.9 100 aIL2R, FK-506, GC L CirrhHep
N F 50 3.5 4.8 100 aIL2R, RAP, MMF, GC K PN
N M 44 0.7 4.4 162 CsA, GC, MMF K Alport syndrome
N M 45 0.7 10.6 136 FK-506, GC, MMF K chronic graft
rejection
N F 59 0.4 9.0 129 aIL2R, FK-506, MMF,GC K PN
N M 44 0.3 9.3 129 FK-506, MMF, GC K IgA nephropathy
N M 51 0.3 3.8 142 FK-778, FK-506, GC L CirrhHep
Y M 51 0.7 4.7 133 ATG, FK-506, RAP, GC K, P DM I
Y F 48 0.7 6.6 108 ATG, FK-506, RAP, GC K, P DM I
Y F 29 0.3 8.0 105 ATG, FK-506, MMF, GC K, P DM I
Y F 24 0.4 7.9 112 ATG FK-506, RAP, GC K, P DM I
Y M 41 0.5 7.1 155 ATG, FK-506, MMF, GC K, P DM II
*no, N; yes, Y;
{male, M; female, F;
§C-reactive protein ,CRP (normal values: 0–0.6 mg/dl);
¤normal values: 3.8–10.5 G/l; hemoglobin, Hb (normal values: 120–157 g/l).
{cyclosporine A, CsA; mycophenolate mofetil, MMF; glucocorticoids, GC; monoclonal anti-human IL-2 receptor antibodies (daclizumab, zenapax
TM), aIL2R; tacrolimus,
FK-506; rapamycine, RAP; monoclonal anti-human CD52 antibodies (alemtuzumab, campath
TM), anti-CD52 Ab; leflunomide analogue FKK-778, FKK-778; ATG Fresenius,
ATG.
Decompensated cirrhosis hepatis, CirrhHep; diabetes mellitus with nephropathy, DM; glomerulonephritis, GN; Kidney, K; lung, L; pancreas, P; polycystic nephropathy,
PC; transplant, TX.
doi:10.1371/journal.pone.0033939.t001
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+ and
CD28
2CD4
+ T-cell subsets in a dose- and time-dependent manner
(Figures 2B, C and D). Stimulation with 3–300 mg/ml ATG-F for
18 hours led to a mean 4.3 times higher apoptosis rate in CD28
2
compared to CD28
+CD4
+ T-cells. The effect of 30 mg/ml ATG-F
on apoptosis was first detected after 2 hours of stimulation and was
maximal after 24 hours in both CD4
+ T-cell subsets. Notably,
depletion of CD28
2 T-cells in vitro was incomplete with ATG-F at a
dose of 100 mg/ml corresponding to in vivo blood concentrations
after treatment with rabbit ATGs [8].
Antilymphocyte globulin triggered apoptosis of CD4
+ T-
cells partially depends on activation of caspases, but not
on the Fas-receptor or IL-2 pathway
A Cathepsin-B- and Fas-receptor mediated mechanism were
analysed to investigate the underlying mechanisms of apoptosis
induced in CD4
+CD28
2 T-cells by ATG-F.
Earlier studies had suggested that ATGs induced T-cell
apoptosis by a Cathepsin-B-dependent mechanism [10]. Our T-
cells from short term cell lines incubated with the broad-spectrum
caspase inhibitor benzyloxycarbonyl (Cbz)-Val-Ala-Asp(OMe)-
fluoromethylketone (zVAD-fmk) before stimulation with ATG-F
resulted in a partial reversion of ATG-F evoked apoptosis at a
dosage of 100 mg/ml in both CD4
+ T-cell subsets (each with
P=0.043; Figure 3A). This effect of zVAD-fmk on ATG-F caused
apoptosis was 9.8 times greater in CD4
+CD28
2 compared to
CD4
+CD28
+ T-cells (P=0.043).
As submitogenic ATG dosages (10–100 mg/ml) induce the
expression of the Fas-receptor (Apo-1, CD95) and Fas-ligand (Fas-
L, CD95-L) on activated lymphocytes resulting in Fas-mediated
apoptosis [9], we then studied a possible ATG-F-triggered Fas-
receptor mediated pathway of apoptosis in CD28
+ and
CD28
2CD4
+ T-cell subsets. Short term cell lines were pre-
incubated with the inhibiting anti-Fas Ab ZB4, blocking the
interaction between Fas-receptor and Fas-L, before addition of the
activating anti-Fas Ab CH11 (positive control) or ATG-F. The
inhibiting anti-Fas Ab ZB4 reversed the effect of the activating
CH11 in both, CD28
+ and CD28
2CD4
+ T-cell subsets, but had
no effect on ATG-F induced apoptosis in both CD4
+ T-cell subsets
at a dosage of 100 mg/ml (Figure S1), thus rendering a Fas-
receptor dependent effect of ATG-F improbable.
As the next step forward we analysed the effects of prednisolon-
21-hydrogensuccinate, FK506 and cyclosporine A (CsA) on ATG-
F-induced cell death as these immunosuppressive agents interfere
with the IL-2 pathway, as IL-2 is required for acquisition of
susceptibility to Fas-mediated apoptosis regulating the transcrip-
tion and surface expression of FasL on lymphocytes [42]. As
shown in Figure 3B, the addition of prednisolon-21-hydrogensuc-
cinate partially reversed ATG-F caused apoptosis in both, CD28
+
and CD28
2CD4
+ T-cell subsets (each with P=0.028) with a 4.1
greater effect in CD4
+CD28
2 T-cells (P=0.028). However,
FK506 and CsA had no effect on ATG-F evoked apoptosis in
both CD4
+ T-cell subsets, thus excluding a possible role of the IL-
2 pathway on ATG-F induced apoptosis.
Chemokine receptors and transendothelial migration:
down-regulation of T helper 1 type chemokine receptors
on CD4
+CD28
2 T-cells by antilymphocyte globulins
The expression of chemokine receptors and leukocyte trafficking
were studied as possible targets of ATG-F effects. Stimulation of
peripheral blood mononuclear cells (PBMCs) with ATG-F at a
dosage of 100 mg/ml for 4 hours resulted in a preferential down-
regulation of T helper (Th) 1 type chemokine receptors CCR-5
(mean difference between ATG-F and rabbit IgG stimulated cells:
220.7% out of CD28
2 vs. 23.6% out of CD28
+CD4
+ T-cells,
P=0.028, Figure 4A), CXCR-3 (231.7% vs. 217.3%, P=0.028,
Figure 4B) and CX3CR-1 (251.9% vs. 21.3%, P=0.028,
Figure 4C) as well as the central memory adhesion molecule
CD62L (217.7% vs. 26.5%, P=0.028, Figure 4E) on
CD4
+CD28
2 T-cells compared to CD28
+ T-cells. The surface
expression of Th2 type CCR-4 slightly increased on CD4
+CD28
2
(+2.8% positive cells, P=0.028, Figure 4D) but not on CD28
+ T-
cells and the surface expression of the central memory chemokine
receptor CCR-7 was differentially influenced by ATG-F with an
up-regulation on CD4
+CD28
2 (+4.5%, P=0.028) and a down-
regulation on CD4
+CD28
+ T-cells (226.3%, P=0.028, Figure 4F).
The transendothelial migration assay was performed to
investigate the functional consequences of ATG-F mediated
changes of chemokine receptor expression. Based on the results
of CX3CR-1 reported above we used the recombinant human
chemokine fractalkine (sFKN, CX3CL-1) as a ligand. The
chemokine receptor CX3CR-1 was almost exclusively expressed
on CD4
+CD28
2 T-cells and strongly influenced by ATG-F
treatment. Transendothelial migration evoked by sFKN was
partially reversed by the pre-incubation of CD4
+ isolated T-cells
with 100 mg/ml ATG-F for 2 hours (expressed as transmigration
index with 1.460.3 vs. 1.060.6; P=0.033; data not shown).
Cytokineproductionmediatedbysupramitogenicdosages
of antilymphocyte globulins in CD4
+CD28
2 T-cells
General symptoms induced by a massive cytokine release in vivo
occur even hours after ATG administration. To investigate the
possible contribution of CD28
2 T-cells to these adverse reactions
at the lymphocyte level, cytokine production of CD4
+CD28
2 was
tested upon stimulation with ATG-F in vitro.
Figure 1. Treatment with polyclonal antilymphocyte globulins
induces depletion of circulating CD3
+CD4
+CD28
2 T-cells in
transplant recipients. Prevalences of peripheral circulating
CD3
+CD4
+CD28
2 T-cells in 16 age- and sex-matched healthy controls,
5 allograft recipients before and 6 hours after the application of ATG-F
and 11 control patients before and 6 hours after organ transplantation.
Data are given as mean6standard error of the mean (SEM).
doi:10.1371/journal.pone.0033939.g001
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CD4
+ subsets. Incubation of cells with ATG-F at dosages of 3–
300 mg/ml led to the activation of both, CD28
2 and CD28
+CD4
+
T-cell subsets as indicated by increased CD25 expression (Figure
S2). Application of ATG-F at dosages of 300 mg/ml and 1000 mg/
ml for 4 hours stimulated the production of IFN-c and TNF-a but
not that of IL-4 in both CD4
+ T-cell subsets. 1000 mg/ml ATG-F
resulted in a 6.2 times and 4.6 times higher effect on IFN-c and
TNF-a production, respectively, in CD28
2 T-cells compared to
their CD28
+CD4
+ T-cell counterparts (Figures 5A and B).
Discussion
Recent studies indicate that pro-inflammatory CD28
2 T-cells
persist over years and include most of the oligoclonally expanded
T-cells. The clonal outgrowth of these CD4
+CD28
2 T-cells is
associated with defects in apoptotic pathways caused by inade-
quate upregulation of bcl-2 [24] and Fas-associated death domain-
like IL-1-converting enzyme-like inhibitory protein, an inhibitor of
Fas signalling that is normally degraded in T-cells following
activation in the presence of IL-2 [25]. Clinically, these specific T-
cells are responsible for the chronicity and relapsing nature of
immune-mediated rheumatic diseases. Thus, depletion of pro-
inflammatory, cytotoxic CD3
+CD4
+CD28
2 T-cells by ATG-F
treatment in vivo provides a promising new therapeutic concept.
For this effect we demonstrated increased in vitro apoptosis of
CD4
+CD28
2 T-cells compared to CD28
+ T-cells that was
partially regulated by caspases and a yet undefined IL-2
independent mechanism inhibited by prednisolon-21-hydrogen-
succinate:
(1) Previous reports had shown that supramitogenic doses of
ATGs led to apoptosis of peripheral blood lymphocytes from
healthy donors and myeloma cells depending on caspases,
particularly on Cathepsin B [10,43]. Indeed, caspase-mediat-
ed apoptotic pathways are still functional in CD4
+CD28
2 T-
cells, as the broad spectrum caspase inhibitor zVAD-fmk
significantly reduced ATG-F induced cell death.
(2) Concerning ATG-induced apoptosis of pre-activated lympho-
cytes by either Fas-receptor/FasL-dependent pathways [9,10],
Figure 2. Antilymphocyte globulins preferentially trigger apoptosis in CD4
+CD28
2 T-cell subsets in vitro. (A) Influence of different
doses of ATG-F on the prevalence of CD3
+CD4
+CD28
2 T-cells in one representative patient. ATG-F or rabbit IgG (rIgG) were applied for 18 hours, as
indicated. (B) Representative histograms showing ATG-F induced apoptosis measured by AnnexinV staining in various doses in comparison to
unspecific rabbit IgG by three colour FACS analysis. Gates were set on lymphocytes (forward and sideward scatter) as well as on CD4
+CD28
+ and
CD4
+CD28
2 cells (not shown), and markers according to the negative control. ATG-F induced apoptosis in both, CD28
+ and CD28
2CD4
+ T-cell
subsets in a dose- (n=6) (C) and time dependent manner (30 mg/ml ATG-F, n=6) (D) measured by AnnexinV staining in flow cytometry. Data are
given as mean (bars) and standard deviation (lines) for CD4
+CD28
+ (white) and CD4
+CD28
2 T-cells (grey). To account for the different rate of
apoptosis in unstimulated CD28
+ and CD28
2CD4
+ T-cells, AnnexinV
+ cells are depicted as the ratio of ATG-F versus rabbit IgG stimulated cells. An
asterisk indicates significant differences (P,0.05) between CD28
+ and CD28
2CD4
+ T-cell subsets. Significances between rabbit IgG and ATG-F evoked
apoptosis were found at doses of 30–300 mg/ml ATG-F in CD4
+CD28
+ and at doses of 3–300 mg/ml ATG-F in CD4
+CD28
2 T-cells (each with P,0.05).
In the time course the ATG-F triggered effect on apoptosis was first detectable after 2 hours in both CD4
+ T-cell subsets (each with P,0.05).
doi:10.1371/journal.pone.0033939.g002
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+CD28
2 T-cells, but was not
influenced by the neutralizing anti-Fas-antibody ZB4, sug-
gesting that the described defects in the Fas-receptor/FasL
pathway of CD4
+CD28
2 T-cells cannot be restored by ATG-
F treatment [25].
(3) The role of IL-2 for ATG-F induced apoptosis of
CD4
+CD28
2 T-cells remains unclear. As IL-2 signalling has
been shown to enhance susceptibility to Fas-receptor/FasL
mediated apoptosis, we expected IL-2 inhibition to decrease
the apoptosis-rate of CD4
+CD28
+ T-cells, but not to affect
CD4
+CD28
2 T-cells [9,42]. Surprisingly, the IL-2 inhibitors
FK506 and CsA had no effect on ATG-F evoked apoptosis in
any CD4
+ T-cell subpopulations, whereas the addition of
prednisolon-21-hydrogensuccinate resulted in a partial reduc-
tion of apoptosis in both CD28
+ and CD28
2CD4
+ T-cell
subsets. It can only be speculated that prednisolon-21-
hydrogensuccinate influences apoptosis of CD4
+ T-cells by
IL-2 independent mechanisms and that the divergences
between our and previous results concerning FK506 and
CsA are caused by differences in the experimental settings [9]:
Our analyses were performed with a different ATG
preparation and shorter pre-incubation times. Besides, we
used T-cells from short term cells lines instead of freshly
isolated lymphocytes activated with phytohemagglutinin [9].
Apart from their pro-apoptotic effects on lymphocytes, ATGs
are known to be immunomodulatory influencing leukocyte
chemotaxis and trafficking [11,12]. As apoptosis of CD4
+CD28
2
T-cells was incomplete after incubation with submitogenic doses of
ATG-F in our in vitro studies but in vivo treatment resulted in
depletion of CD3
+CD4
+CD28
2 T-cells, we tested whether ATG-
F forces increased homing of this pro-inflammatory T-cell
subpopulation. Indeed CD4
+CD28
2 T-cells are unique to
combine receptors of short-lived memory effector cells and long-
lived central memory cells enabling these cells to home to both,
peripheral inflammatory lesions as well as organized lymphoid
organs [44]. Interestingly, our experiments showed a down-
regulation of the Th1 type and effector memory receptors CCR-5,
CXCR-3 and CX3CR-1 as well as the central memory adhesion
molecule CD62L on CD4
+CD28
2 T-cells after stimulation with
ATG-F in vitro. Besides, ATG-F reduced migration of
CD4
+CD28
2 T-cells in a transendothelial assay confirming the
functional relevance of changed chemokine and chemokine
receptor expression. Taken together, these data suggest that
depletion of CD4
+CD28
2 T-cells in vivo is not caused by increased
cell trafficking and that other, yet undefined mechanisms may
contribute to complete disappearance of peripheral circulating
CD4
+CD28
2 T-cells.
In the patients treatment of ATG-F is concerned to induce
lymphocytic cytokine release causing the ‘‘first dose syndrome’’.
Our in vitro cytokine data for the CD4
+CD28
+ T-cells are in line
with previous studies revealing an ATG-F promoted production of
IFN-c and TNF-a with a shift toward a Th1 cytokine profile
[45,46]. The effect of ATG-F on CD4
+CD28
2 T-cells, however,
was much stronger leading to a concept that high pre-treatment
levels of circulating CD4
+CD28
2 T-cells could be a risk factor for
infusion related adverse reactions after high dosages of ATG-F.
Because of the small sample size of our cohort we were unable to
test this hypothesis in this study.
The small and heterogenous group of enrolled transplant
recipients in our in vivo study and the short follow-up period of
patients at one single time point after ATG-F application is
certainly the main limitation of this study. Thus, a type 1 error
with overestimation of the ATG-F induced effect of the presented
in vivo data cannot be excluded. Phenotypical and functional
differences between CD4
+CD28
2 T-cells from patients $50 years
and those from younger people were previously suggested;
however, we observed no influence of age on ATG-F mediated
Figure 3. Antilymphocyte globulin-triggered apoptosis of CD4
+ T-cells partially depends on activation of caspases. To investigate the
underlying mechanisms of apoptosis induction in CD4
+ T-cells by ATG-F (A) a caspase-mediated mechanism (n=5) was analysed by AnnexinV
staining in flow cytometry. (B) As the immunosuppressive agents prednisolon-21-hydrogensuccinate (glucocorticoid), FK506 and cyclosporine A are
known to interfere with the interleukin (IL)-2 pathway, their influence on ATG-F mediated apoptosis was examined in CD28
+ and CD28
2CD4
+ T-cell
subsets (n=6). Data are given as mean (bars) and standard deviation (lines) for CD4
+CD28
+ (white) and CD4
+CD28
2 T-cells (grey). An asterisk
indicates significant differences (P,0.05) between CD28
+ and CD28
2CD4
+ T-cell subsets. Depicting significances broken and continuous lines were
used for CD28
+ and CD28
2CD4
+ T-cells, respectively.
doi:10.1371/journal.pone.0033939.g003
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limitation of our study is the use of one ATG product, namely
ATG-F, for our in vitro and in vivo analyses, although different ATG
preparations are currently available. As ATGs contain a mixture
of multiple antibodies to various lymphocyte surface antigens, we
cannot exclude that other types of ATG may have different effects
on CD4
+CD28
2 T-cells [9,47,48]. Our data on ATG-F evoked
apoptosis measured by AnnexinV FACS analysis show a certain
variability possibly related to the examinations of samples from
different patients and the individually different susceptibility to
ATG-F. Besides, AnnexinV staining was the only (although well
established) method to determine apoptosis. Apoptosis induction,
however, was reversible thus excluding unspecific effects and the
conclusions drawn from different experiments were the same:
CD4
+CD28
2 T-cells, otherwise known as resistant to apoptosis
are more susceptible to ATG-F evoked apoptosis than their
CD28
+ counterparts. Concerning the assays to explore the in vitro
mechanisms, we identified 2 potential pathways triggering
apoptosis of CD4
+CD28
2 T-cells after ATG-F stimulation, but
additional mechanisms restoring the capacity of CD4
+CD28
2 T-
cell to undergo apoptosis most likely exist as the addition of the
broad spectrum caspase inhibitor zVAD-fmk and prednisolon-21-
hydrogensuccinate resulted only in partial reversions of ATG-F
evoked apoptosis. Thus, we could not explain why CD4
+CD28
2
T-cells totally disappear from peripheral blood after ATG-F
therapy despite incomplete in vitro apoptosis and downregulation of
homing and effector chemokine receptors. One untested, but
possible explanation is an upregulation of CD28 on surviving
(non-apoptotic) CD4
+CD28
2 T-cells upon ATG-F treatment,
however, future research is needed to clarify this issue. We
Figure 4. Down-regulation of Th1 type chemokine and leukocyte homing receptors by antilymphocyte globulins in CD4
+CD28
2 T-
cells. Dose dependent in vitro effects of ATG-F on surface expression of the type 1 chemokine receptors (A) CCR-5, (B) CXCR-3, (C) CX3CR-1, the type
2 chemokine receptor (D) CCR-4, and the central memory receptors (E) CD62L and (F) CCR-7 on CD4
+ T-cell subsets in comparison to rabbit IgG (rIgG)
(n=6). Data are given as mean (bars) and standard deviation (lines) for CD4
+CD28
+ (white) and CD4
+CD28
2 T-cells (grey). An asterisk indicates
significant differences (P,0.05) between CD28
+ and CD28
2CD4
+ T-cell subsets. Depicting significances between rabbit IgG and ATG-F induced
modulation of chemokine receptor expression broken and continuous lines were used for CD28
+ and CD28
2CD4
+ T-cells, respectively.
doi:10.1371/journal.pone.0033939.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33939concede, that the long-term consequences of ATG-F-induced
depletion of circulating peripheral and tissue infiltrating
CD4
+CD28
2 T-cells in chronic inflammatory diseases is unclear
and may result in a driving force to re-fill-up peripheral niches
achieving T-cell homoeostasis. Also this issue has to be addressed
by a longitudinal follow-up study.
In summary, ATG-F is the first substance effectively depleting
circulating CD3
+CD4
+CD28
2 T-cells in patients undergoing
organ transplantation at least over 6 hours. ATG-F preferentially
induces apoptosis of this CD4
+CD28
2 T-cell subset in vitro and this
effect is partially reversed by the broad-spectrum caspase inhibitor
zVAD-fmk and prednisolon-21-hydrogensuccinate. Additionally,
stimulation with ATG-F results in a predominant Th1-type
activation with IFN-c and TNF-a cytokine production, as well
as functional down-regulation of effector memory and central
memory chemokine receptors of CD4
+CD28
2 T-cells.
Methods
Statement of the ethics committee
The ethics committee of the Innsbruck Medical University
granted the study during their session number 225/4.19, study
number UN2239 on the 01.02.2005.
Patients’ recruitment and antilymphocyte globulins
Sixteen consecutive recipients of either kidney or lung
transplant were enrolled into the study (Table 1, patients’
characteristics). Blood samples were drawn from five patients
(38.6611.8 years old, 3 female patients) receiving ATG-F
(Fresenius Biotech, Gra ¨felfing, Germany) preoperatively in a
dosage of 8 mg/kg body weight and from 11 patients without
ATG-F treatment (50.566.7 years old, 2 female patients).
Percentages of CD28
2 out of the CD3
+CD4
+ PBMCs were
determined before and 6 hours after ATG-F application by flow
cytometry. Laboratory investigators were blinded for ATG-F
treatment of patients.
For in vitro analyses consecutive patients suffering from chronic
inflammatory diseases with a prevalence of peripheral
CD3
+CD4
+CD28
2 T-cells $5% were included into the study.
Patients with immune-mediated diseases were selected, as
functional differences between CD28
2 T-cells from different
diseases or in the elderly have not been detected in earlier studies.
Blood samples were drawn after informed and written consent as
approved by the ethics committee of the Innsbruck Medical
University, Austria (AN 2239 - 225/4.19, PN 10/2005).
Within the context of this report, ATG is used to refer to either
antithymocyte or antilymphocyte globulins in general, whereas
ATG-F is used to refer to antilymphocyte globulins offered by
Fresenius Biotech.
Cell preparation and short term cell lines
Peripheral venous blood was drawn and PBMCs were isolated
by Ficoll density gradient centrifugation. Short-term cell lines were
established from fresh PBMCs stimulated with immobilized anti-
CD3 mAb (OKT3; eBioscience, San Diego, CA, USA) for
18 hours. Cells were then maintained in logarithmic growth with
densities between 0.5 and 2610
6 cells/ml in RPMI 1640
containing 10% foetal calf serum, 2 mmol/l L-glutamine, 50 U/
ml penicillin, 5 mg/ml streptomycin (all from PAA Laboratories,
Linz, Austria) and 20 U/ml recombinant human IL-2 (Prepro-
tech, London, UK). Experiments were performed later than 7 days
after initiation of the culture.
Stimulation and blocking experiments
For comparison of the dose-dependent effect of ATG-F on
apoptosis as well as expression of the activation marker IL-2Ra
(CD25) on CD28
+ and CD28
2CD4
+ T-cell subsets, CD3
+ T-cells
from short term cell lines were incubated with submitogenic (3, 10,
30 mg/ml), mitogenic (100 mg/ml) and supramitogenic dosages
(300 mg/ml) of ATG-F (Batch# RU10L-2), 5 mg/ml unspecific
rabbit IgG (Fresenius) as a negative control or 5 mg/ml OKT-3 as a
positive control for 18 hours. The used ATG-F concentrations
correspond with the expected serum concentrations of rabbit ATG
at 80 to 200 mg/ml [8,9]. For evaluation of a caspase-dependent
mechanism of ATG-F induced apoptosis in CD4
+ T-cell subsets,
cells from short term cell lines were pre-incubated with 500 mMo f
the broad-spectrum caspase inhibitor benzyloxycarbonyl (Cbz)-Val-
Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk; Bachem, Weil am
Rhein, Germany, gift from Prof. Bernhard D, PhD) for 2 hours
before stimulation with ATG-F (n=5). To test a Fas-receptor
mediated pro-apoptotic effect of ATG-F on CD4
+ T-cell subsets,
cells from short term cell lines were pre-incubated with 2 mg/ml
(n=6) of the Fas-blocking antibody ZB4 (IgG1, Biomed Immuno-
tech Vienna, Austria) for at least 2 hours before addition of ATG-F,
5 mg/ml of the Fas-activating antibody CH11 (IgM, Immunotech,
gift from PD Eller K, MD) as a positive control and 5 mg/ml
unspecific rabbit IgG (Fresenius) as a negative control. To analyse
whether IL-2 interfering pathways influence ATG-F induced
apoptosis, cells from short term cell lines were treated with 1 mg/
ml prednisolon-21-hydrogensuccinate, 200 ng/ml FK506 or 1 mg/
ml CsA for 3 hours before addition of either 100 mg/ml ATG-F or
5 mg/ml unspecific rabbit IgG (Fresenius) (n=6). Cells were then
stimulated for 18 hours with 100 mg/ml ATG-F and apoptosis was
evaluated by AnnexinV binding using flow cytometry.
For analysis of the time course of ATG-F on apoptosis of CD4
+
T-cell subsets, CD3
+ T-cells from short term cell lines were
incubated with 30 mg/ml ATG-F at various time points (2, 4, 8, 12
and 24 hours).
To evaluate the influence of ATG-F on chemokine receptor
expression, PBMCs were treated with ATG-F at various dosages
(10, 30, 100 mg/ml) for 4 hours, and chemokine receptor
expression was then evaluated by flow cytometry.
Three colour surface staining, intracellular staining for
cytokine production and flow cytometry
Surface staining of Ficoll density gradient purified PBMCs was
performed using fluorescein isothiocyanate (FITC)-conjugated
Figure 5. Production of pro-inflammatory cytokines by polyclonal antilymphocyte globulins in CD4
+CD28
2 T-cells. (A) To test
whether ATG-F treatment leads to cytokine production of CD4
+ T-cell subsets in vitro, stimulation with rabbit IgG (rIgG), phorbol 12-myristate 13-
acetate (PMA)/ionomycin, and ATG-F at a dose of 300 mg/ml or 1000 mg/ml and intracellular cytokine staining for IFN-c, TNF-a and IL-4 was
performed (n=6). Whiskers box plots show 50% of cases within the boxes and all data excluding mavericks between the end-points of the whiskers
(lines). An asterisk indicates significant differences (P,0.05) between CD28
+ and CD28
2CD4
+ T-cell subsets. Depicting significances between rabbit
IgG, PMA/ionomycin and ATG-F induced cytokine expression broken and continuous lines were used for CD28
+ and CD28
2CD4
+ T-cells, respectively.
(B) Representative dot plot and histograms depicting ATG-F induced production of TNF-a after 4 hours of stimulation in supramitogenic dosages of
300 mg/ml and 1000 mg/ml in comparison to stimulation with unspecific rIgG and PMA/ionomycin in the presence of brefeldin A. Gates were set on
lymphocytes (forward and sideward scatter) as well as on CD4
+CD28
+ and CD4
+CD28
2 cells, and markers according to the negative control.
doi:10.1371/journal.pone.0033939.g005
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phycoerythrin (PE)-conjugated anti-CD28, CXCR-3, CCR-4,
CCR-7; and peridinin chlorophyll protein-conjugated (PerCP)
anti-CD4 and CD3 mAb (all from Becton Dickinson, San Diego,
CA, USA; except for anti-CCR-5, CX3CR-1 antibodies pur-
chased from MBL International, Woburn, MA, USA).
For intracellular staining, cells were stimulated either with 5 mg/
ml unspecific rabbit IgG (Fresenius), 25 ng/ml phorbol 12-
myristate 13-acetate (PMA) and 1 mg/ml ionomycin (Sigma,
Munich, Germany) or 300 mg/ml and 1000 mg/ml ATG-F in
the presence of 10 mg/ml brefeldin A for 4 hours (Sigma). The
supramitogenic dosages of ATG-F with 300 mg/ml and 1000 mg/
ml were chosen, because induction of cytokine production are
dose-dependent and doses as high as 1000 mg/ml stimulated TNF-
a production in a previous study using horse ATG [49]. After cell
surface staining for CD28 and CD4 with subsequent fixation and
permeabilisation, cells were stained with FITC-conjugated anti-
IFN-c, TNF-a and IL-4 mAb or control Ig (R&D Systems, Inc.,
MN, USA). After fixation with 1% cell fix (Becton Dickinson) cells
were analysed on a FACS-Calibur flow cytometer (Becton
Dickinson). Data were analysed using WinMDI software (Version
2.8, Joseph Trotter, Scripps Research Institute, La Jolla, CA,
USA).
Transendothelial migration
For transmigration assays CD4
+ T-cells were isolated from short
term cell lines using magnetic bead labelled anti-CD4 mAb as well
as Midi-MACS
TM and Mini-MACS
TM columns according to the
manufacturer’s instructions (Miltenyi Biotech, Amsterdam, The
Netherlands). Purity of the isolated CD4
+ T-cell fraction was more
than 90% as determined by flow cytometry.
Human umbilical vein endothelial cells (HUVEC) from fresh
placenta cords were isolated and grown to confluence at 37uC
(humidified atmosphere). HUVECs of passages 1 and 2 were used
for the transendothelial migration assays.
Six mm polyester filter inserts with 3 mM pores (Transwell
TM
Clear 3472, Costar, Cambridge, MA) were prepared by overnight
incubation in 10% foetal calf serum containing medium prior to
seeding cells. 3.3610
4 HUVECs were seeded per insert. HUVECs
formed a tight permeability barrier within 3–5 days. Medium was
changed three times a week.
Confluent HUVEC monolayers grown on Transwell
TM growth
supports were washed twice with phosphate-buffered saline (PBS).
5 ng/ml soluble recombinant human CX3CL-1 (sFKN, R&D
Systems) or medium alone (control) were added to the lower
compartment. Thereafter 0.1 ml of MACS
TM-sorted CD4
+ T-cell
suspension (2.0610
6 cells/ml) - untreated or pre-incubated with
100 mg/ml ATG-F for 2 hours - were added to the upper
compartments and lymphocytes were allowed to migrate across
the endothelial monolayers for 4 hours.
Transmigration of lymphocytes was quantified as described
previously with some modification [50]. The number of migrated
cells was determined by measuring the fluorescence of 29,79-bis-(2-
carboxyethyl)-5,6-carboxyfluorescein-acetoxymethylester loaded
cells using a microtitre plate reader (Cytofluor
TM, PerSeptive
Biosystems, USA). Fluorescence was read at 530625 nm. Each
independent experiment was performed in duplicate. Data are
expressed as transmigration index (TI) representing the ratio of the
number of migrated lymphocytes across the endothelial monolay-
ers in the presence or absence of the stimulating chemokine.
Statistical analysis
Results were expressed as mean and standard deviation (SD).
The Mann-Whitney test was used to compare between indepen-
dent groups, and the Wilcoxon ranking test to compare between
paired data from the CD28
+ and the CD28
2 T-cell compartments
and the prevalence of CD3
+CD4
+CD28
2 T-cells before and after
treatment with ATG-F as appropriate. The TI of ATG-F treated
and non-treated lymphocytes was compared by the paired
Student’s T-test. All statistical analyses were performed using the
SPSS program, version 16.0 (Chicago, IL, USA). P,0.05 was
considered to be statistically significant.
Supporting Information
Figure S1 Antilymphocyte globulin-triggered apoptosis
of CD4
+ T-cells is Fas-receptor independent. To test
whether the underlying pro-apoptotic effect of ATG-F on CD4
+
T-cell subsets was Fas-receptor mediated, cells from short term cell
lines (n=6) were pre-incubated with 2 mg/ml of the Fas-blocking
antibody ZB4 for at least 2 hours before addition of ATG-F, 5 mg/
ml of the Fas-activating antibody CH11 as a positive control and
5 mg/ml unspecific rabbit IgG as a negative control. Apoptosis was
evaluated after 18 hours of incubation by AnnexinV binding using
flow cytometry. Data are given as mean (bars) and standard
deviation (lines) for CD4
+CD28
+ (white) and CD4
+CD28
2 T-cells
(grey). An asterisk indicates significant differences (P,0.05)
between CD28
+ and CD28
2CD4
+ T-cell subsets. Depicting
significances broken and continuous lines were used for CD28
+
and CD28
2CD4
+ T-cells, respectively.
(TIFF)
Figure S2 Activation by polyclonal antilymphocyte glob-
ulins in CD4
+CD28
2 T-cells. As ATG-F has known mitogenic
properties, the expression of the lymphocytic activation marker
CD25 was studied by three colour FACS analysis (n=6). Data are
given as mean (bars) and standard deviation (lines) for
CD4
+CD28
+ (white) and CD4
+CD28
2 T-cells (grey). To account
for the different activation rate in unstimulated CD28
+ and
CD28
2CD4
+ T-cells, CD25
+ cells are depicted as the ratio of
ATG-F versus rabbit IgG (rIgG) stimulated cells. An asterisk
indicates significant differences (P,0.05) between CD28
+ and
CD28
2CD4
+ T-cell subsets. Significances between rabbit IgG and
ATG-F triggered expression of CD25 were found at doses of 30–
300 mg/ml ATG-F in both CD4
+ T-cell subsets (each with
P,0.05).
(TIFF)
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